Cancer incubator secures further financing
SIVA continues backing our Incubator so we can help cancer start-ups succeed
Oslo Cancer Cluster Incubator has been awarded NOK 3,5 million to continue supporting cancer innovators during 2023. The funds come from SIVA, a governmental enterprise facilitating a national infrastructure for innovation.
Why are these funds important? Well, the road is long from a promising innovation is born until it becomes a solution that improves patients’ lives. An innovator often needs support to make their idea into a commercial product.
Precision therapy against cancer
This was the case with Kongsberg Beam Technology, founded by Per Håvard Kleven who had invented a digital solution to improve proton therapy, based on expertise from the Kongsberg defence industry.
The company was admitted into the Accelerator programme at Oslo Cancer Cluster Incubator in 2019. The incubator team worked closely with the company and helped with everything from setting up a business plan, developing a company strategy and recruiting management, to attracting the company’s first investors.
Kerstin Johansson, CEO of Kongsberg Beam Technology, one of the companies in the Incubator that has received help from SIVA.
“If it wasn’t for Oslo Cancer Cluster Incubator, Kongsberg Beam Technology wouldn’t be where we are today.”
“If it wasn’t for Oslo Cancer Cluster Incubator, Kongsberg Beam Technology wouldn’t be where we are today. From being a one-man company, we have grown to a semi-virtual company with a mix of employees and CRO/service companies with key competences for the road to commercialise our product MaMa-K. To date we have attracted NOK 50,4 million in private investments and public funding. We strongly believe that with our solution, MaMa-K software intended for radiation therapy the clinical benefits will be significantly better and cancer patients will have a much better life with less side effects after the treatment,” said Kerstin Jakobsson, CEO of Kongsberg Beam Technology.
A melting pot for innovation
Oslo Cancer Cluster Incubator is the only cancer incubator among the total 35 companies accepted into the SIVA’s new ten-year Incubator programme starting 2023. The Incubator offers business development services, state-of-the-art laboratories, and access to a global cancer community.
Oslo Cancer Cluster Incubator have state-of-the-art labs that are shared between academics and private companies. Photo: Christopher Olssøn
A multitude of languages can be heard between the international researchers as you walk down the hallways. When peering into the labs, you see academics working side-by-side with private companies. This is a true melting pot for health innovation.
“Oslo Cancer Cluster Incubator is uniquely situated next to Oslo University Hospital and can provide the network in oncology that early-stage companies in cancer need.”
“Oslo Cancer Cluster Incubator is uniquely situated next to Oslo University Hospital and can provide the network in oncology that early-stage companies in cancer need. We are now expanding the Innovation Park to make room for more companies, who are in dire need of our facilities and expertise. This is good for the companies, it benefits the patients and adds value to Norwegian society,” said Ketil Widerberg, CEO and Chairman of Oslo Cancer Cluster Incubator.
The Incubator is situated in Oslo Cancer Cluster Innovation Park, right next to the Cancer Research Institute and a stone’s throw away from the Oslo University Hospital (a Comprehensive Cancer Centre). Photo: Christian Tandberg
- Read more on Oslo Cancer Cluster Incubator’s website
The post Cancer incubator secures further financing first appeared on Oslo Cancer Cluster.
